🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to health experts.

A Global Challenge

Cases of gonorrhoea are increasing worldwide, with data suggesting over 82 million new cases each year. Especially elevated rates are observed in the African continent and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an important and timely advancement in the context of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices at this time.”

Medical experts are deeply concerned about the surge in antibiotic-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring found that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Receive Clearance

One new antibiotic, marketed under the name a brand name, was cleared by the US FDA in mid-December for use against gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts believe that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, also received approval in close succession. This drug, which is also used to treat UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The charitable organization GARDP worked alongside the drug firm its industry partner to see it through.

“This milestone marks a huge turning point in the therapy of superbug gonorrhoea, which until now has been outpacing our drug pipeline.”

Clinical Trial Data and Global Access

Based on data released by a prominent scientific publication, the new drug eradicated over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the existing first-line therapy, which uses an injection and a pill. The trial involved nearly 1,000 participants from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the authority to register and commercialise the drug in many low-income and middle-income countries.

Doctors directly involved have shared optimism. The availability of a easy-to-administer therapy of this kind is hailed as a "game-changer" for gonorrhoea control. This is deemed essential to lessen the impact of the illness for patients and to stop the proliferation of untreatable gonorrhoea worldwide.